Prosigna Package Insert
To download the Prosigna Package Insert, select a language from the options below:

nCounter® Dx Analysis System User Manual
To download the nCounter Dx Analysis System User Manual, select a language from the options below:
List of publications
Intrinsic subtypes

PAM50

Prosigna
Verification Study
TransATAC Clinical Verification Study
Click here to access the TransATAC clinical verification study article, available through Journal of Clinical Oncology.
Clinical validation
ABCSG-8 Clinical Validation Study
Click here to access the ABCSG-8 clinical validation study article.
Analytical validation
Analytical Validation Study
Click here to access the analytical validation study, available through BMC Cancer.
NCCN Patient Resources
Click here to access the NCCN Patient Resources page.
Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive (Stage II or IIIA) early-stage breast cancer to be treated with adjuvant endocrine therapy.
© 2014-2017 NanoString Technologies, Inc. All rights reserved. NanoString, the NanoString Technologies logo, nCounter, Prosigna and the Prosigna logo are trademarks and/or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.